The risk of developing a blood clot after having COVID-19 is eight times higher than after receiving the Oxford-AstraZeneca vaccine, according to a study from the University of Oxford.
Cerebral venous thrombosis (CVT) has occurred in 39 people out of a million COVID-19[female[feminine patients, compared to about five in a million AstraZeneca stroke.
COVID updates live from UK and around the world
In the study of more than 500,000 coronavirus patients, the risk has been reported to be about 100 times higher than normal after infection.
Many countries have limited the use of the vaccine to certain age groups or have suspended its roll-out – with Denmark even permanently withdrawing the vaccine from its immunization schedule – following reports on very rare cases of blood clots.
The British medical regulator said the vaccine was still safe and effective, but had limited its use in those under 30 because this age group is less at risk of becoming seriously ill with coronavirus.
However, the Oxford study suggested that about a third (30%) of reports of CVT after COVID-19 infection were in people under the age of 30.
Scientists said the technology used in the Oxford-AstraZeneca vaccine, which harnesses an adenovirus, was associated with a slightly increased risk of blood clots.
It is the same explanation for the Johnson & Johnson vaccine, which was discontinued in the United States after a handful of reports of clotting there.
In more than 480,000 people who received Pfizer or Moderna…
More information about this article Read More
This notice was published: 2021-04-15 10:39:00